| abstract |
The present invention concerns novel compounds represented by thenFormula:n nwherein: A is R 1 q (R 3 R 60 N) m (Z)(NR 2 ) n ; m and q are each 0 or 1, with the proviso thatnwhen q is 1, m is 0 and when q is 0, m is 1; Z is C=O or SO 2 ; n is 1 with the provisonthat, when Z is C=O, m is 1; X is -NH-, -CH 2 -, or -OCH 2 -; Y is 2-imidazoline,n2-oxazoline,n2-thiazoline, or 4-imidazole; R 1 is H, lower alkyl, or phenyl, with the provisonthat, when R 1 is H, m is 1; R 2 , R 3 , R 60 are each independently H, lower alkyl, ornphenyl; R 4 , R 5 , R 6 , and R 7 are each independently hydrogen, lower alkyl, -nCF 3 , lowernalkoxy, halogen, phenyl, lower alkeny, hydroxyl, lower alkylsulfonamido, or lowerncycloalkyl, wherein R 2 and R 7 optionally may be taken together to form alkylene ornalkenylene of 2 to 3 atoms in an unsubstituted or optionally substituted 5-orn6-memberednring, wherein the optional substituents on the ring are halo, lower alkyl, orn-CN, with the proviso that, when R 7 is hydroxyl or lower alkylsulfonamido, then X isnnot -NH- when Y is 2-imidazoline. The compounds include pharmaceuticallynacceptable salts of the above. In the above formula A may be, for example,n(R 1 SO 2 NR 2 -), (R 3 R 60 NSO 2 NR 2 -), or (R 3 R 60 NCONR 2 -). The invention also includes thenuse of the above compounds, and compositions containing them, as alpha 1A/1L nagonists in the treatment of various disease states such as urinary incontinence,nnasal congestion, priapism, depression, anxiety, dementia, senility, Alzheimer's,ndeficiencies in attentiveness and cognition, and eating disorders such as obesity,nbulimia, and anorexia. |